105 related articles for article (PubMed ID: 11860770)
1. [An observation of the immuno-persistence after inoculating with the domestic BRD II strain rubella vaccine among infants and young children].
Xu A; Song L; Wang C; Wang A; Xu Q; Xiao Z; Wang S; Li M; Hao S; Li Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Apr; 21(2):117-20. PubMed ID: 11860770
[TBL] [Abstract][Full Text] [Related]
2. [A serological study on the immunization schedule at first dose of domestic BRD II strain rubella vaccine].
Xu AQ; Song LZ; Hao SZ
Zhonghua Liu Xing Bing Xue Za Zhi; 1997 Jun; 18(3):156-9. PubMed ID: 9812464
[TBL] [Abstract][Full Text] [Related]
3. [Immune response of rubella vaccine in the populations with different age groups].
Xiong XW; Diao LD; Yan XL
Zhonghua Liu Xing Bing Xue Za Zhi; 1997 Aug; 18(4):227-9. PubMed ID: 9812525
[TBL] [Abstract][Full Text] [Related]
4. [A study on the level of antibody against measles through maternal-fetal transfer and the immuno-response to measles vaccine among 4 to 7 month olds].
Liu BY; Feng ZX; Xu AQ
Zhonghua Liu Xing Bing Xue Za Zhi; 1995 Oct; 16(5):263-5. PubMed ID: 8706090
[TBL] [Abstract][Full Text] [Related]
5. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
6. A rubella outbreak investigation and BRD-II strain rubella vaccine effectiveness study, Harbin city, Heilongjiang province, China, 2010-2011.
Xu H; Gao X; Bo F; Ma J; Li Y; Fan C; Jiang L; Ma Y; Luo H; An Z
Vaccine; 2013 Dec; 32(1):85-9. PubMed ID: 24188756
[TBL] [Abstract][Full Text] [Related]
7. Antibody response after measles immunization.
Ariyasriwatana C; Kalayanarooj S; Pattamadilok S
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S701-6. PubMed ID: 14700170
[TBL] [Abstract][Full Text] [Related]
8. Study of young women vaccinated against rubella virus for 10 years in Taiwan.
Lin DB; Kao CL; Lee CY
Southeast Asian J Trop Med Public Health; 1996 Dec; 27(4):707-14. PubMed ID: 9253871
[TBL] [Abstract][Full Text] [Related]
9. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
Gans HA; Yasukawa LL; Alderson A; Rinki M; DeHovitz R; Beeler J; Audet S; Maldonado Y; Arvin AM
J Infect Dis; 2004 Jul; 190(1):83-90. PubMed ID: 15195246
[TBL] [Abstract][Full Text] [Related]
10. Seroconversion after measles vaccination at nine and fifteen months of age.
Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of HI antibody titer against rubella virus to determine the effect of mass vaccination in Tehran.
Soleimanjahi H; Bamdad T; Fotouhi F; Roustai MH; Faghihzadeh S
J Clin Virol; 2005 Oct; 34(2):153-4. PubMed ID: 16076562
[TBL] [Abstract][Full Text] [Related]
12. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants.
D'Angio CT; Boohene PA; Mowrer A; Audet S; Menegus MA; Schmid DS; Beeler JA
Pediatrics; 2007 Mar; 119(3):e574-9. PubMed ID: 17332177
[TBL] [Abstract][Full Text] [Related]
13. EPI vaccines-induced antibody prevalence in 8-9 year-olds in The Gambia.
Viviani S; Mendy M; Jack AD; Hall AJ; Montesano R; Whittle HC
Trop Med Int Health; 2004 Oct; 9(10):1044-9. PubMed ID: 15482396
[TBL] [Abstract][Full Text] [Related]
14. [Analysis on the changing of age patterns among rubella patients after rubella vaccine immunization for children in Shandong Province, China].
Xu Q; Xu AQ; Song LZ; Zhang L; Xiao ZK; Wang CY; Li MS; Wang AL; Li Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Nov; 26(11):861-3. PubMed ID: 16676605
[TBL] [Abstract][Full Text] [Related]
15. [Investigations on the dependency of hemagglutination inhibition titers against rubella virus on the number and quality of antibody molecules (author's transl)].
Hoppe G
Zentralbl Bakteriol A; 1981; 249(2):143-51. PubMed ID: 7269848
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
18. Congenital rubella syndrome due to infection after maternal antibody conversion with vaccine.
Ushida M; Katow S; Furukawa S
Jpn J Infect Dis; 2003 Apr; 56(2):68-9. PubMed ID: 12824690
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
Sultana R; Rahman MM; Hassan Z; Hassan MS
Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
